WARNING - FDA records indicate that this drug has been recalled.
Amino Acids label

Amino Acids

Amino Acids Recall

Get an alert when a recall is issued.

B. Braun Medical Inc
Product Description: 15% Amino Acids Injection PBP Glass, 1000 mL, Catalog No. S3200-SS, Pharmacy Bulk Package, Not For Direct Infusion, For Intravenous Use, Sterile, Single Dose Container, Rx Only, B Braun Medical Inc., Irvine, CA 92614-5895, NDC 0264-3200-55
Status: Ongoing
City: Irvine
State: CA
Country: US
Voluntary/Mandated: Voluntary: Firm Initiated
Initial Firm Notification: Letter
Distribution Pattern: Nationwide, Puerto Rico and Spain
Classification: Class I
Product Quantity: 18,288 units
Reason For Recall: Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.
Recall Initiation Date: 20131121
Report Date: 20140507

Side Effects & Adverse Reactions

Administration of amino acids solutions at excessive rates or to patients with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Conservative doses of amino acids should be given to these patients, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid administration should be discontinued and the patient’s clinical status re-evaluated.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.

Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when:

—   Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy;

—   Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks;

—   Tube feeding methods alone cannot provide adequate nutrition.

History

There is currently no drug history available for this drug.

Other Information

Plenamine™ 15% Amino Acids Injection in a Pharmacy Bulk Package is a sterile, clear, nonpyrogenic solution of essential and nonessential amino acids for intravenous infusion in parenteral nutrition following appropriate dilution.

Plenamine™ 15% in a Pharmacy Bulk Package is not for direct infusion. It is a sterile dosage form which contains several single doses for use in a pharmacy admixture program in the preparation of intravenous parenteral fluids.

Each 100 mL contains:

*
Acetate from Lysine Acetate, USP and acetic acid used for pH adjustment.
 Essential Amino Acids    
 Lysine (from Lysine Acetate, USP)  1.18  g
 Leucine, USP  1.04  g
 Phenylalanine, USP  1.04  g
 Valine, USP  960  mg
 Isoleucine, USP  749  mg
 Methionine, USP  749  mg
 Threonine, USP  749  mg
 Tryptophan, USP  250  mg
        
 Nonessential Amino Acids    
 Alanine, USP  2.17  g
 Arginine, USP  1.47  g
 Glycine, USP  1.04  g
 Histidine, USP  894  mg
 Proline, USP  894  mg
 Glutamic Acid  749  mg
 Serine, USP  592  mg
 Aspartic Acid, USP  434  mg
 Tyrosine, USP  39  mg
 Sodium Metabisulfite, NF added  30  mg
 Water for Injection, USP    qs
        
 Essential Amino Acids  6.7  g
 Nonessential Amino Acids  8.3  g
 Total Amino Acids  15.0  g
 Total Nitrogen  2.37  g
 Acetate*  151  mEq/L
 Osmolarity (calculated)  1383  mOsmol/L
 pH 5.6 (5.2–6.0)    

The formulas for the individual amino acids are as follows:

 Essential Amino Acids
 Lysine Acetate  H2N(CH2)4CH(NH2)COOH•CH3COOH
 Leucine  (CH3)2CHCH2CH(NH2)COOH
 Phenylalanine   Chemical Structure
 Valine  (CH3)2CHCH(NH2)COOH
 Isoleucine  CH3CH2CH(CH3)CH(NH2)COOH
 Methionine  CH3S(CH2)2CH(NH2)COOH
 Threonine  CH3CH(OH)CH(NH2)COOH
 Tryptophan   Chemical Structure
 Nonessential Amino Acids
 Alanine  CH3CH(NH2)COOH
 Arginine  H2NC(NH)NH(CH2)3CH(NH2)COOH
 Glycine  H2NCH2COOH
 Histidine   Chemical Structure
 Proline   Chemical Structure
 Glutamic Acid  HOOC(CH2)2CH(NH2)COOH
 Serine  HOCH2CH(NH2)COOH
 Aspartic Acid  HOOCCH2CH(NH2)COOH
 Tyrosine   Chemical Structure

Amino Acids Manufacturers

  • B. Braun Medical Inc.
    Amino Acids | B. Braun Medical Inc.
    No Recall

    Amino Acids | B. Braun Medical Inc.

    Amino Acids | B. Braun Medical Inc.

    The appropriate daily dose of amino acids to be used with dextrose or with dextrose and intravenous fat emulsion will depend upon the metabolic status and clinical response of the patient as therapy proceeds. Doses which achieve nitrogen equilibrium or positive balance are the most desirable. The dosage on the first day should be approximately half the anticipated optimal dosage and should be increased gradually to minimize glycosuria; similarly, withdrawal should be accomplished gradually to avoid rebound hypoglycemia.

    Fat emulsion coadministration should be considered when prolonged (more than 5 days) parenteral nutrition is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat free TPN.

    The amount administered is dosed on the basis of amino acids/kg of body weight/day. In general, two to three g/kg of body weight for neonates and infants with adequate calories are sufficient to satisfy protein needs and promote positive nitrogen balance. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).

    DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE

    Plenamine™ 15% in a Pharmacy Bulk Package is not intended for direct infusion. The container closure may be penetrated only once using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Once the closure is penetrated, the contents should be dispensed as soon as possible; the transfer of contents must be completed within 4 hours of closure entry. The bottle may be stored at room temperature (25°C) after the closure has been entered. Date and time of container entry should be noted in the area designated on the container label.

    When using Plenamine™ 15% in patients with a need for fluid volume restriction, it can be diluted as follows:

    Volume Amount Final Concentration  Plenamine™ 15%  500 mL  75 g  7.5%  Dextrose 70%  250 mL  175 g  17.5%  Intralipid® 20%  250 mL  50 g  5.0%

    This will provide 1395 kilocalories (kcal) per 1000 mL of admixture with a ratio of 118 non-protein calories per gram of nitrogen and an osmolarity of 1561 mOsmol/L.

    In patients where the need for fluid restriction is not so marked, either of the following regimens may be used dependent upon the energy needs of the patient.

    Volume Amount Final Concentration  Plenamine™ 15%  500 mL  75 g  3.75%  Dextrose 50%  1000 mL  500 g  25%  Intralipid® 20%  500 mL  100 g  5%

    This will provide 1500 kcal per 1000 mL of admixture with a ratio of 228 non-protein calories per gram of nitrogen and an osmolarity of 1633 mOsmol/L.

    Volume Amount Final Concentration  Plenamine™ 15%  500 mL  75 g  3.75%  Dextrose 30%  1000 mL  300 g  15%  Intralipid® 10%  500 mL  50 g  2.5%

    This will provide 935 kcal per 1000 mL of admixture with a ratio of 158 non-protein calories per gram of nitrogen and an osmolarity of 1128.5 mOsmol/L.

    A. Total Parenteral Nutrition (Central Infusion)

    In unstressed adult patients with no unusual nitrogen losses, a minimum dosage of 0.1 gram nitrogen (4.2 mL of Plenamine™ 15%) plus 4.4 grams (15 calories) of dextrose per kilogram of body weight per day are required to achieve nitrogen balance and weight stability. Intravenous fat emulsion may be used as a partial substitute for dextrose. This regimen provides a ratio of 150 non-protein calories per gram of nitrogen.

    For patients stressed by surgery, trauma or sepsis, and those with unusual nitrogen losses, the dosage required for maintenance may be as high as 0.3 to 0.4 grams of nitrogen (13 to 17 mL Plenamine™ 15%) per kilogram of body weight per day, with proportionate increases in non-protein calories. Periodic assessment of nitrogen balance of the individual patient is the best indicator of proper dosage. Volume overload and glycosuria may be encountered at high dosage, and nitrogen balance may not be achieved in extremely hypermetabolic patients under these constraints. Concomitant insulin administration may be required to minimize glycosuria. Daily laboratory monitoring is essential.

    Use of an infusion pump is advisable to maintain a steady infusion rate during central venous infusion.

    B. Peripheral Nutrition

    In patients for whom central venous catheterization is not advisable, protein catabolism can be reduced by peripheral use of diluted Plenamine™ 15% plus non-protein calorie sources. Dilution of 250 mL Plenamine™ 15% in 750 mL of 10% dextrose will reduce the osmolarity to a level (724 mOsmol/L) which is more favorable to the maintenance of the integrity of the walls of the veins. Intravenous fat emulsion can be infused separately or simultaneously; if infused simultaneously the fat emulsion will provide a dilution effect upon the osmolarity while increasing the energy supply.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    To reduce the risk of bacterial contamination, all intravenous administration sets should be replaced at least every 24 hours. Usage of admixtures must be initiated within 24 hours after mixing. If storage is necessary during this 24 hour period, admixtures must be refrigerated and completely used within 24 hours of beginning administration.